Reforgene named a 2024 Future Healthcare Top 100 company for the second consecutive year

From May 7 to 10, 2024, the 8th VBEF Future Healthcare Ecosystem Exhibition was held at the Beiren Yichuang International Convention and Exhibition Center in Beijing. The conference, themed "New Youth", interpreted the pioneering spirit of healthcare innovation trailblazers. On the evening of May 9, the conference released the Future Healthcare Top 100 list. Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene"), focused on innovative R&D of gene editing medicines, was again selected into the 2024 Future Healthcare Top 100, Innovative Medicine and Biologics TOP100, following 2023.

Receiving this honor consecutively shows that Reforgene's achievements in gene editing technology and drug innovation have been affirmed by industry experts, industry observers and analysis institutions. "New Youth" means passion, hope and mission, and responsibility, commitment and dreams. Reforgene continuously upholds the philosophy of innovation for life, is driven by gene editing technology, crosses uncharted territory, leads the wave of gene editing drug innovation, and provides accessible, curative medicines for more patients with serious diseases.

2024 Future Healthcare Top 100

Founded in 2015 by VB100, VBDATA and Danke Research Institute, the Future Healthcare Top 100 list is the first domestic list for innovative healthcare companies targeting non-listed enterprises. It aims to select Chinese innovative healthcare providers that truly represent the future of healthcare, discover the core strength of China's future healthcare industry, and promote the innovation and transformation of the health industry.

After eight years of practice and exploration, the "Future Healthcare Top 100" selection has received strong support and recognition from many investment institutions and enterprises, and has become an investment bellwether in the healthcare field, leading the development and investment trends of China's healthcare innovation now and for some time to come, providing reference for the subsequent financing of innovative enterprises.